Dermapharm Holding Se · XETR:DMP

Dermapharm — Q3 2020 Earnings Presentation

17 slides from Dermapharm's earnings presentation, Nov 16, 2020

  1. Slide 1: Investor and Analyst Conference Call Q3 2020

    INVESTOR AND ANALYST CONFERENCE CALL Q3 2020 Grünwald, 16 November 2020

  2. Slide 2: Disclaimer

    Disclaimer This publication includes statements, estimates, opinions and projections with respect to the anticipated future performance of Dermapharm Holding SE (together with its consolidated subsidiaries, “Dermapharm”) and such statements, estimates, opinions and projections (“Forward- Looking Sta

  3. Slide 3: Agenda

    AGENDA 1. Highlights Q3 2020 2. Financial figures Q3 2020 3. Outlook FY 2020 4. Q & A

  4. Slide 4: Agenda: Highlights Q3 2020

    AGENDA 1. Highlights Q3 2020 2. Financial figures Q3 2020 3. Outlook FY 2020 4. Q & A

  5. Slide 5: Dermapharm's strategy proves resilience

    Highlights Q3 2020 Dermapharm’s strategy proves resilience COVID-19 • Continuous ability to produce and deliver • Flexibility allows capturing of opportunities • Cooperation and supply agreement for the production of the COVID-19 vaccine BNT162b2 with BioNTech Update on • Further integration into De

  6. Slide 6: Agenda: Financial figures Q3 2020

    AGENDA 1. Highlights Q3 2020 2. Financial figures Q3 2020 3. Outlook FY 2020 4. Q & A

  7. Slide 7: Dermapharm Group: Strong overall growth despite COVID-19 pandemic

    Dermapharm Group Strong overall growth despite COVID-19 pandemic Total Revenue (€m) EBITDA(1) (€m, adjusted) Comments EBITDA Margin +11.5% YoY 25.7% 24.1% Significant revenue growth of 11.5% to €577.2m, due to 577.2  revenue contribution of latest acquisition in 9M 2020 517.6  increased organic gr

  8. Slide 8: Branded pharmaceuticals and other healthcare products

    Branded pharmaceuticals and other healthcare products Further growth expansion driven by integration of acquisition Revenue (€m) EBITDA(1) (€m, adjusted) Comments EBITDA Margin +20.2% YoY 41.2% 37.4% Revenues up by 20.2% to €331.9m  mainly based on contribution of Fitvia and Allergopharma  signifi

  9. Slide 9: Parallel import business

    Parallel import business Higher market share in growing PI market Revenue (€m) EBITDA (€m) Comments EBITDA Margin +2.4% YoY 3.9% 3.3% Revenues increased by 2.4% to €189.6m  demand for parallel imported originator products was flattening out  increased market share in growing market, #5 in German P

  10. Slide 10: Herbal extracts

    Herbal extracts Lower demand due to COVID-19 pandemic Revenue (€m) EBITDA(1) (€m, adjusted) Comments EBITDA Margin -1.1% YoY 28.8% 23.0% Revenues decreased by 1.1% to €55.7m, comprising Euromed  lower global demand for herbal extracts due to COVID-19 pandemic could not be compensated yet 55.7 56.3

  11. Slide 11: Earnings before tax (Group EBT)

    Earnings before tax (Group EBT) Result increased due to M&A and business growth Earnings before tax (EBT)(1) (€m) Comments EBT Margin 16.0% 15.6%  EBT increased by 9.3% to €90.3m (unadjusted) resulting in a margin of 15.6% +9.3% YoY Mainly influenced by 90.3  lower depreciation and amortisation (€

  12. Slide 12: Strong cash flows and cash conversion

    Strong cash flows and cash conversion Reflecting strong dedication to future growth Cash flow and cash conversion(1)(€m) Comments in % of Group EBITDA Cash conversion 47.8% 47.8%  CF from operating activities increased mainly influenced by  increased EBT in 9M 2020 and  decreased tax payments 64

  13. Slide 13: Balance sheet of Dermapharm Group

    Balance sheet of Dermapharm Group Balance Sheet as of 30 September 2020 (€m) Comments  Total assets increased to €1,221m (31 December 2019: €1,045m) 1,221 1,221  Non-current assets increased to €809m (31 December 2019: €692m) driven by integration of Allergopharma  Current assets increased to €41

  14. Slide 14: Agenda: Outlook FY 2020

    AGENDA 1. Highlights Q3 2020 2. Financial figures Q3 2020 3. Outlook FY 2020 4. Q & A

  15. Slide 15: Growth strategy on track - conforming guidance 2020

    Growth strategy on track - conforming guidance 2020 Revenues 2020 positive growth of 12-15% vs. previous year (€700.9m) EBITDA 2020 positive growth of 8-10% (adjusted) vs. previous year (€177.6m) Growth rates are based on organic growth supported by new launches of in-house developments. Guidance fo

  16. Slide 16: Agenda: Q & A

    AGENDA 1. Highlights Q3 2020 2. Financial figures Q3 2020 3. Outlook FY 2020 4. Q & A

  17. Slide 17: Investor contact

    Investor contact Britta Hamberger Investor Relations & Corporate Communications Dermapharm Holding SE E-Mail: ir@dermapharm.com Phone: +49 (0) 89 641 86 233

Dermapharm Holding — Q3 2020 Earnings Presentation on 6ix